Contribution: Industrial Research Assistance Program – Contributions to Firms
Phoenix Molecular Designs Ltd.
$481,596.00
Combination treatment development involving orally available small molecule Ribosomal S6 Kinase (RSK) inhibitor PMD-026
FY 2019-20 · 2019-07-01
Summary
The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for triple-negative breast cancers (TNBC). This project seeks to develop an advanced formulation for delivery, evaluate the performance of the lead in combination therapies and evaluate the ability of the lead compound to overcome resistance in in vitro models (in anticipation of future in vivo studies).
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
808104087
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2019-07-01 | 2019-20 | $400,948.00 |
| 1 | 2019-07-01 | 2019-20 | $451,896.00 |
| 3 | 2019-07-01 | 2019-20 | $461,596.00 |
| 4 | 2019-07-01 | 2019-20 | $461,596.00 |
| 5 | 2019-07-01 | 2019-20 | $481,596.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 20,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 20 000 dollars.
Agreement End Date
2021-03-31
Agreement Number
931368
Agreement Start Date
2019-07-01
Agreement Title
Combination treatment development involving orally available small molecule Ribosomal S6 Kinase (RSK) inhibitor PMD-026
Agreement Title (French)
Développement d'un traitement combiné faisant appel à un inhibiteur de la kinase S6 ribosomique « Ribosomal S6 Kinase (RSK) » de petite molécule disponible par voie orale PMD-026
Agreement Type
Contribution
Agreement Value
$481,596.00
Amendment Date
2021-03-22
Amendment Number
5
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for triple-negative breast cancers (TNBC). This project seeks to develop an advanced formulation for delivery, evaluate the performance of the lead in combination therapies and evaluate the ability of the lead compound to overcome resistance in in vitro models (in anticipation of future in vivo studies).
Description (French)
L'entreprise a identifié un composé phare avec une nouvelle cible à développer en tant que traitement potentiel pour les cancers du sein triple-négatifs « triple-negative breast cancers (TNBC) ». Ce projet vise à développer une formulation avancée pour l'administration, à évaluer la performance de la sonde dans les thérapies combinées et à évaluer la capacité du composé principal à surmonter la résistance dans les modèles in vitro (en prévision des études in vivo futures).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Quadra
Federal Riding (French)
Vancouver Quadra
Federal Riding Number
59039
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
808104087
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Phoenix Molecular Designs Ltd.
Recipient Postal Code
V6R 1E5
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2019-2020-Q2-931368
